Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies (NASDAQ:BSGM) has secured up to $1.1 billion in growth financing through definitive agreements with institutional investors. The financing includes $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months.
The company, which recently merged with Streamex Exchange Corporation, aims to become one of Nasdaq's largest public holders of gold bullion and plans to tokenize the $142 trillion commodities market using Streamex's real-world asset (RWA) platform powered by Solana blockchain. The debentures have a 24-month maturity with 4% annual interest, convertible into common stock.
The transaction, expected to close around October 7, 2025, was led by Cantor Fitzgerald & Co., Clear Street LLC, and Needham & Company as placement agents, with CIBC World Markets acting as Strategic Advisor.
BioSig Technologies (NASDAQ: BSGM) and Streamex Exchange Corporation have appointed Mitch Williams, CFA, as their Chief Investment Officer. Williams, a former executive at OppenheimerFunds and Wafra Inc., brings over 20 years of capital markets experience to the combined company. At Wafra Inc., he achieved more than 3-fold growth in Global Equity assets and delivered top-quartile performance consistently.
As CIO, Williams will lead the companies' strategic vision and commodity tokenization initiatives, focusing on penetrating the $142.85 trillion global commodity market through real world asset (RWA) tokenization solutions. He will report directly to CEO Henry McPhie. Williams, who was previously an early investor and Strategic Advisor to Streamex, views RWA tokenization as a scalable technology and sees Streamex as a unique investment opportunity combining fiat currency hedging with recurring revenue.
BioSig Technologies (NASDAQ: BSGM) has appointed Mitch Williams, CFA, as Chief Investment Officer following its acquisition of Streamex Exchange Corporation. Williams, a former executive at OppenheimerFunds and Wafra Inc., brings over 20 years of capital markets experience to advance the company's mission in real world asset tokenization and commodity markets.
At Wafra Inc., Williams demonstrated exceptional performance by growing assets more than 3-fold and maintaining top-quartile performance. At OppenheimerFunds, he was the top-ranked equity analyst leading the firm's flagship fund. In his new role, Williams will oversee the company's strategic vision and commodity tokenization initiatives within the $142.851 trillion global commodity market, reporting directly to CEO Henry McPhie.
BioSig Technologies (NASDAQ: BSGM) and Streamex Exchange Corporation have completed their share exchange transaction, transforming into a company focused on real-world asset tokenization, particularly in the commodities sector. The deal positions the combined entity to tap into the $142.85 trillion global commodity market.
Key leadership changes include Streamex's Co-Founder Henry McPhie becoming CEO and joining the Board, while Co-Founder Morgan Lekstrom will serve as Chairman. Former BioSig CEO Anthony Amato will remain on the Board. Notable strategic additions include Frank Giustra, founder of Wheaton Precious Metals and GoldCorp, as Strategic Investor and Advisor on Commodities, and Mathew August as Strategic Advisor on US Capital Markets.
BioSig Technologies (NASDAQ: BSGM) has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant pivot from medical technology to real-world asset tokenization. Under the agreement, Streamex will become a wholly-owned subsidiary of BioSig, with Streamex shareholders receiving 75% of BioSig's fully diluted common stock. The combined company will be led by Streamex's Co-Founder Henry McPhie as CEO, while Morgan Lekstrom will serve as Chairman.
The transaction brings notable strategic advisors, including Frank Giustra, founder of Wheaton Precious Metals and GoldCorp, positioning the company to tap into the $142.85 trillion global commodity market through blockchain technology. Initially, Streamex shareholders will receive 19.9% of BioSig's outstanding common stock, with the full 75% stake subject to shareholder approval.
BioSig Technologies (NASDAQ: BSGM) has signed a Letter of Intent (LOI) to merge with Streamex Exchange Corporation in an all-stock transaction. The merger aims to create a publicly listed real-world asset tokenization company on the Nasdaq. Streamex offers a technology stack featuring a fully developed primary issuance and decentralized exchange infrastructure for on-chain commodity markets. The platform provides commodity-focused real-world asset tokenization infrastructure and a financing platform designed to streamline the investment process, increase capital availability, and expand investor opportunities.
BioSig Technologies (BSGM) has successfully regained full compliance with Nasdaq Capital Market listing requirements. The company received formal notice on March 24, 2025, confirming it has met the minimum stockholders' equity threshold of $2.5 million as per Listing Rule 5550(b), resolving its previously disclosed deficiency.
The medical technology company, known for its PURE EP™ Platform that provides precision in intra-cardiac signal visualization for electrophysiologists during ablation treatments of cardiovascular arrhythmias, maintains its focus on advancing operational goals and strengthening market position through innovation and strategic partnerships.
BioSig Technologies (NASDAQ: BSGM) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, meeting Nasdaq Listing Rule 5550(a)(2) requirements. Nasdaq has officially closed the prior bid price deficiency matter as of November 13, 2024. The company's PURE EP™ Platform, which is FDA 510(k) cleared, provides real-time cardiac signal visualization for targeted cardiac ablation procedures.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
